FY2024 EPS Forecast for ProPhase Labs Decreased by Analyst

ProPhase Labs, Inc. (NASDAQ:PRPH) – Investment analysts at Diamond Equity dropped their FY2024 earnings estimates for ProPhase Labs in a report released on Thursday, February 13th. Diamond Equity analyst H. Diamond now forecasts that the company will post earnings of ($1.27) per share for the year, down from their prior forecast of ($1.23). The consensus estimate for ProPhase Labs’ current full-year earnings is ($1.23) per share. Diamond Equity also issued estimates for ProPhase Labs’ Q1 2025 earnings at ($0.18) EPS, Q2 2025 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.11) EPS and FY2025 earnings at ($0.56) EPS.

Separately, StockNews.com assumed coverage on shares of ProPhase Labs in a research report on Monday. They set a “sell” rating on the stock.

ProPhase Labs Price Performance

PRPH opened at $0.44 on Monday. The company has a quick ratio of 1.33, a current ratio of 1.47 and a debt-to-equity ratio of 0.48. ProPhase Labs has a 52-week low of $0.22 and a 52-week high of $7.48. The company has a 50 day moving average of $0.55 and a two-hundred day moving average of $1.51. The company has a market cap of $10.48 million, a P/E ratio of -0.35 and a beta of -0.37.

Institutional Trading of ProPhase Labs

Institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC grew its position in shares of ProPhase Labs by 33.2% during the fourth quarter. Renaissance Technologies LLC now owns 286,485 shares of the company’s stock worth $217,000 after acquiring an additional 71,375 shares during the last quarter. HighTower Advisors LLC grew its position in shares of ProPhase Labs by 32.2% during the fourth quarter. HighTower Advisors LLC now owns 236,781 shares of the company’s stock worth $179,000 after acquiring an additional 57,736 shares during the last quarter. Sheets Smith Wealth Management bought a new position in shares of ProPhase Labs during the fourth quarter worth about $158,000. Geode Capital Management LLC grew its position in shares of ProPhase Labs by 26.6% during the fourth quarter. Geode Capital Management LLC now owns 203,528 shares of the company’s stock worth $154,000 after acquiring an additional 42,793 shares during the last quarter. Finally, Perritt Capital Management Inc grew its position in shares of ProPhase Labs by 129.1% during the fourth quarter. Perritt Capital Management Inc now owns 190,000 shares of the company’s stock worth $144,000 after acquiring an additional 107,068 shares during the last quarter. Institutional investors own 9.45% of the company’s stock.

ProPhase Labs Company Profile

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.